Search
Nautilus Biotechnology Inc
NAUTAdd to Watchlist
2.150USD
-0.140-6.11%
Close 11-05 16:00（ET）
273.85MMarket Cap
LossP/E TTM
After-hours 19:38 (ET)2.080USD-0.120-5.46%
After-hours 19:38 (ET)Today
-6.11%
5 Days
-31.53%
1 Month
+14.97%
6 Months
-24.83%
Year to Date
+10.26%
1 Year
+42.38%
Key Figures
2.240Open
2.245High
671.51KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.53%Turnover Ratio
2.290Prev. Close
1.990Low
1.41MTurnover
LossP/E Static
2.40P/B
0.00%Div Yield TTM
-28.16%ROA
4.31052wk High
0.10Volume Ratio
-70.78MNet Profit
127.37MShares
-0.4517EPS TTM
0.74Beta
-33.69%ROE
0.84152wk Low
17.25%Amplitude
89.74%Gross Margin
273.85MMarket Cap
-7.19Reward/Risk
7.42%Risk Rate
Nautilus Biotechnology Inc's Score
-0.36vs previous score
Forecast9.00
Financial Health5.52
Technical6.13
Valuation Dimensions7.42
Institutional Confidence3.00
Risk Assessment1.68
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Nautilus Biotechnology Inc Technical Analysis
Technical Indicators
Strong sell
Summary
Sell
Moving Average
Neutral
Nautilus Biotechnology Inc Latest Earnings Call Transcripts
Nautilus Biotechnology (NAUT) Q3 2026 Earnings Call: Voyager Launch Roadmap and Cash Runway
Nautilus Biotechnology’s Q3 2026 earnings call covered $0.2 million revenue, a $15.6 million net loss, Voyager’s 2027 launch and cash runway into Q1 2028.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
-0.12/-0.14
Revenue / Forecast
234.00K/206.25K
Nautilus Biotechnology Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolNAUT
Number of employees155
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Mallick (Parag) | 16.28% |
| Andreessen Horowitz | 13.89% |
| Patel (Sujal M) | 13.74% |
| Perceptive Advisors LLC | 9.91% |
| Shareholder Types | Proportion |
|---|---|
| Individual Investor | 32.06% |
| Venture Capital | 18.66% |
| Investment Advisor | 10.56% |
| Private Equity | 10.07% |
Related Instruments
-3.76%
-1.45%
-2.24%
-2.27%
-1.85%
-1.14%
-3.80%
-3.96%
-4.46%
-2.96%
-1.19%
-1.65%
+0.24%
-1.18%
-1.45%
-6.55%
-2.98%
+0.62%
+2.25%
-3.93%Popular Instruments
51030.400
-468.700 (-0.91%)
26868.800
+233.600 (+0.88%)
7357.700
+0.800 (+0.01%)
12797.000
-1.000 (-0.01%)
57458.000
+192.000 (+0.34%)
6165.900
-11.900 (-0.19%)
90.867
+0.834 (+0.93%)
344.170
-5.340 (-1.53%)
181.600
-18.530 (-9.26%)
4047.440
-51.250 (-1.25%)
FAQs
What is the current price of Nautilus Biotechnology Inc (NAUT)?
The current price of Nautilus Biotechnology Inc (NAUT) is 2.15.
What is the symbol of Nautilus Biotechnology Inc?
The ticker symbol of Nautilus Biotechnology Inc is NAUT.
What is the 52-week high of Nautilus Biotechnology Inc?
The 52-week high of Nautilus Biotechnology Inc is 4.31.
What is the 52-week low of Nautilus Biotechnology Inc?
The 52-week low of Nautilus Biotechnology Inc is 0.84.
What is the market capitalization of Nautilus Biotechnology Inc?
The market capitalization of Nautilus Biotechnology Inc is 273.85M.
Is Nautilus Biotechnology Inc (NAUT) currently rated as Buy, Hold, or Sell?
According to analysts, Nautilus Biotechnology Inc (NAUT) has an overall rating of STRONG BUY, with a price target of 4.00.
What is the Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT)?
The Earnings Per Share (EPS TTM) of Nautilus Biotechnology Inc (NAUT) is -0.45.